Startups toolkit: Why investors want more than patents

For startups, getting a drug to market is a marathon but founders need to think beyond filing patents to win over investors, Marisa Woutersen explores how they can succeed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

WATCH: Aligning innovation, regulation and IP protection

29 October 2024 Experts from Wilson Sonsini, Theravance Bio, Sutro Bipharma, and Addition Therapeutics share insights on managing the intersection of innovation, regulatory compliance, and IP protection in the life sciences industry.

Big Pharma

SPCs outlive patent protections in 91% of cases, new report reveals

24 June 2021 Supplementary protection certificates outlive medicinal patents in more than nine in ten cases, a new report has found.

Europe

Second medical use: a regulatory perspective

8 February 2021 Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.

More features

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

Smart ringleader: Could Ōura’s market dominance be under threat?

Startups toolkit: Why investors want more than patents

More on this story

Editor's picks

Editor's picks

More features